

October 10, 2025

To,
National Stock Exchange of India Limited
'Exchange Plaza' C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol: **AGARWALEYE**

Dear Sir / Madam,

Sub: Submission of Report on Complaints as per SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, as amended from time to time ("SEBI Circular") pursuant to the application for obtaining approval under Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for the proposed scheme of amalgamation of Dr. Agarwal's Eye Hospital Limited ("Transferor Company") with Dr. Agarwal's Health Care Limited ("Transferee Company") and their respective shareholders and creditors ("Scheme") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with rules and/or regulations framed thereunder and the regulations and circulars issued by the Securities and Exchange Board of India (in each case including any statutory modification(s) or re-enactment(s) thereof for the time being in force)

This is with reference to our application for obtaining approval under Regulation 37 of the Listing Regulations for the proposed Scheme.

In terms of paragraph (A)(6) of Part I of the SEBI Circular, a listed entity is required to submit a "Report on Complaints" to the stock exchanges within 7 days of expiry of 21 days from the date of filing of the draft Scheme with the stock exchanges and hosting of the same along with the documents specified in the above SEBI Circular on the website of the stock exchanges and the listed entity.

It may be noted that Dr. Agarwal's Health Care Limited (the Transferee Company) has filed the draft Scheme with National Stock Exchange of India Limited ("**NSE**") under Regulation 37 of the Listing Regulations on September 10, 2025, and the same was hosted on the website of NSE on September 15, 2025.

In view of the above, we hereby submit the Report on Complaints for Dr. Agarwal's Health Care Limited (the Transferee Company) as per the format prescribed under the SEBI Circular, attached as **Annexure A**. The same is also being uploaded on the website of the Company at <https://dragarwals.co.in/dr-agarwals-health-care/#scheme>, in compliance with the SEBI Circular.

Thanking you,

Yours faithfully,

For **Dr. Agarwal's Health Care Limited**

Thanikainathan Arumugam
Company Secretary and Compliance Officer

Dr. Agarwal's Health Care Limited

Regd. Office: 1st Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006.

Corporate Office

3rd Floor, Buhari Towers, No.4 Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006.

Tel: +91 44 4378 7777 | +91 44 4378 7778 | CIN: L85100TN2010PLC075403 | GST No: 33AADCD4418M1ZO

Email: info@dragarwal.com | Website: www.dragarwals.co.in

Annexure A
Period of Complaints Report: September 15, 2025 – October 6, 2025

Part A

Sr. No.	Particulars	Number
1.	Number of complaints received directly	Nil
2.	Number of complaints forwarded by Stock Exchanges/SEBI	Nil
3.	Total Number of complaints/comments received (1+2)	Nil
4.	Number of complaints resolved	NA
5.	Number of complaints pending	NA

Part B

Sr. No.	Name of complainant	Date of complaint	Status (Resolved / Pending)
1.	-	-	-

Thanking you,

Yours faithfully,

For **Dr. Agarwal's Health Care Limited**

Thanikainathan Arumugam
Company Secretary and Compliance Officer